Salvianolic acid B protects against sepsis-induced liver injury via activation of SIRT1/PGC-1α signaling

HONGLING SU1, ZHISHENG MA1, AIXIA GUO1, HONG WU2,3 and XIANGMIN YANG1

Departments of 1Gastroenterology and 2General Surgery, Xidian Group Hospital, Xi’an, Shaanxi 710000; 3Department of General Surgery, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi 710061, P.R. China

Received November 13, 2018; Accepted August 1, 2019

DOI: 10.3892/etm.2020.9020

Abstract. Liver injury occurs frequently during sepsis, which leads to high mortality and morbidity. A previous study has suggested that salvianolic acid B (SalB) is protective against sepsis-induced lung injury. However, whether SalB is able to protect against sepsis-induced liver injury remains unclear. The present study aimed to investigate the effects of SalB on sepsis-induced liver injury and its potential underlying mechanisms. Sepsis was induced in mice using a cecal ligation and puncture (CLP) method. The mice were treated with SalB (30 mg/kg intraperitoneally) at 0.5, 2 and 8 h after CLP induction. Pathological alterations of the liver were assessed using hematoxylin and eosin staining. The serum levels of alanine transaminase (ALT), aspartate aminotransferase (AST), tumor necrosis factor (TNF)-α and interleukin (IL)-6 were measured. The hepatic mRNA levels of TNF-α, IL-6, Bax and Bcl-2 were also detected. The results suggested that treatment with SalB ameliorated sepsis-induced liver injury in the mice, as supported by the mitigated pathologic changes and lowered serum aminotransferase levels. SalB also decreased the levels of the inflammatory cytokines TNF-α and IL-6 in the serum and the liver of the CLP model mice. In addition, SalB significantly downregulated Bax expression and upregulated Bcl-2 expression, and upregulated the expression levels of SIRT1 and PGC-1α. However, when sirtuin 1 (SIRT1) small interfering RNA was co-administered with SalB, the protective effects of SalB were attenuated and the expression levels of SIRT1 and PGC-1α were reduced. In summary, these results indicate that SalB mitigates sepsis-induced liver injury via reduction of the inflammatory response and hepatic apoptosis, and the underlying mechanism may be associated with the activation of SIRT1/PGC-1α signaling.

Introduction

Sepsis is a systemic and severe inflammatory reaction to an infection, and is characterized by multi-organ damage (1). It has been indicated that sepsis is the most common cause of mortality among patients in non-coronary intensive care units (2). Sepsis can lead to various types of organ damage, including liver, brain and cardiac injury (3–5). Inflammation has been demonstrated to play a critical role in the underlying mechanism of sepsis (6). The liver is a pivotal organ in the clearance of bacteria, and liver dysfunction is associated with poor prognosis (7). Notably, the attenuation of liver injury decreases the morbidity and mortality of patients with sepsis (8).

Radix Salvia miltiorrhiza is a traditional Chinese medicine with a long history of use. It has been used in the treatment of several diseases, such as angina pectoris (9) and cerebral ischemia (10). Salvianolic acid B (SalB), is one of the main components of Radix Salvia miltiorrhiza. Previous studies have indicated that SalB exhibits various biological activities, including anti-inflammatory and anti-oxidative effects (11,12). In addition, SalB has been reported to attenuate the induction of lung injury by sepsis (13). However, whether SalB has a protective effect against sepsis-induced liver injury remains unknown. Sirtuin 1 (SIRT1), a nicotinamide adenine dinucleotide-dependent class III histone deacetylase, has been reported to play critical roles in various conditions, including oxidative stress, senescence and inflammation (14,15). Additionally, SIRT1 can activate peroxisome proliferator-activated receptor-γ co-activator 1α (PGC-1α), which is a key regulator in oxidative stress of the mitochondria (16).

Therefore, the current study aimed to investigate the role of SalB in sepsis-induced liver injury and determine whether SIRT1/PGC-1α is involved in the mechanism underlying the protective effect of SalB.

Materials and methods

Animals. Male C57BL/6 mice (8–10 weeks old, 20–22 g, 120 mice in total) were purchased from the Center of
Experimental Animals of Xi'an Jiaotong University. All mice were kept under standard care conditions (humidity, 40-70%; temperature, 18-28°C) with a 12 h light/dark cycle and free access to water and food. The study was performed according to the Guide for the Care and Use of Laboratory Animals (National Institutes of Health Publication no. 85-23, revised 1996) and was approved by the Ethics Committee of Xi'an Jiaotong University (Xi'an, China).

Reagents. SalB (purity >98%) was purchased from Shanghai Winherb Medical Science Co., Ltd. Tumor necrosis factor (TNF)-α (cat. no. DY410) and interleukin (IL)-6 (cat. no. PM6000B) ELISA kits were acquired from R&D Systems, Inc. Alamine aminotransferase (ALT) (cat. no. C009-3-1) and aspartate transaminase (AST) (cat. no. C010-3-1) assay kits were purchased from Nanjing Jiancheng Bioengineering Institute. Antibodies against SIRT1 (cat. no. 9475), Bcl-2 (cat. no. 3498), Bax (cat. no. 14796) and β-actin (cat. no. 4970) were purchased from Cell Signaling Technology, Inc., and the antibody against PGC-1α (cat. no. sc-518025) was obtained from Santa Cruz Biotechnology, Inc.

Experimental protocol. Mice were randomly assigned to five groups (n=24 in each group): i) Sham group; ii) cecal ligation and puncture (CLP) + vehicle group; iii) CLP + SalB (30 mg/kg) group; iv) CLP + SalB + control small interfering RNA (siRNA) group and v) CLP + SalB + SIRT1 siRNA group. The mice in the sham group underwent a sham surgery and vehicle treatment, the CLP + vehicle group received CLP and vehicle treatment, and the CLP + SalB group received CLP surgery and SalB treatment. SalB was dissolved in normal saline (to a concentration of 30 mg/kg) and administered to the mice intraperitoneally at 0.5, 2 and 8 h after the CLP surgery. In the CLP + SalB + SIRT1 siRNA group, SIRT1 siRNA (sense, 5'-UAC AGG GUU ACA GCA AAG U(dTdT)-3' and reverse, 5'-GGT ATG CAC CCA AAG U(dTdT)-3'). Invitrogen; Thermo Fisher Scientific, Inc.) using SYBR Advantage qPCR Master Mix (Takara Bio, Inc.) was used. The RT reaction was performed as previously reported (19). The RNA extraction buffer was TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.). The PrimeScript™ RT Master Mix (Takara Bio, Inc.) was used. The RT reaction was incubated for 15 min at 37˚C and for 5 sec at 85˚C. The sequences of the primers used for qPCR were as follows: TNF-α forward, 5'-TGCTGGAGCAAGCTAAAGG-3' and reverse, 5'-CGAATTTTGAGAAGATGACTCGT-3'; IL-6 forward, 5'-TCAATTTCCAGAACCCGTATGA-3' and reverse, 5'-ACACGGATCAGTCCCAAGA-3'; Bcl-2 forward, 5'-CAGGATGTCGCCACCCAAAGA-3' and reverse, 5'-AGTGAAGAGGCAACCCAG-3'; Bax forward, 5'-CAGGCAGCATCAGTCCCAAGA-3' and reverse, 5'-AGAGGCAACCCAGC-3'; and β-actin forward, 5'-AGAGGGAAA TCGTGGCTGAC-3' and reverse, 5'-CAATATGTTGACTCGTGGCCTG-3'. Relative quantification of the target mRNA was calculated and normalized to β-actin. qPCR was performed using the 7500 Real-Time PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.) using SYBR Advantage qPCR Premix. The thermocycling conditions were as follows: Initial denaturation for 30 sec at 95°C, followed by 40 cycles of 10 sec at 95°C, and 30 sec at 60°C. Relative mRNA expression was calculated using the 2^ΔΔCt method (20).
Caspase-3 activity assay. Relative activity of caspase-3 in the liver tissues of the mice was detected using a caspase-3 colorimetric assay kit (Abcam; cat. no. ab39401) according to the manufacturer’s protocol.

Western blotting. Liver tissue was homogenized in RIPA lysis buffer (Beyotime Institute of Biotechnology) with protease inhibitor by sonication. The proteins were quantified using a bicinchoninic acid assay. Total lysate (40 µg protein/lane) was separated using 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and the separated proteins were transferred to polyvinylidene difluoride (PVDF) membranes. The PVDF membranes were then blocked with 5% non-fat milk prior to incubation with primary antibodies against SIRT1 (1:1,000), PGC-1α (1:500), Bcl-2 (1:1,000), Bax (1:1,000) and β-actin (1:1,000) overnight at 4˚C. The membranes were washed three times, 5 min each, then incubated with appropriate HRP-conjugated secondary antibodies (1:2,000; goat anti-rabbit; cat. no. ab7090; or goat-anti-mouse cat. no. ab97040; Abcam) at room temperature for 2 h. Protein bands were visualized using an ECL Western Blotting Detection reagent (Thermo Fisher Scientific, Inc.). The protein
bands were then detected and quantified using a Bio-Rad imaging system (Bio-Rad Laboratories, Inc.).

**Statistical analysis.** Data in the present study were analyzed using GraphPad Prism 5 software (GraphPad Software, Inc.). Data are expressed as the mean ± SEM. One-way ANOVA followed by Bonferroni multiple comparisons test was used for intergroup comparisons. Fisher’s exact test probability method was used to analyze the survival rate. P<0.05 was considered to indicate a statistically significant difference.

**Results**

**SalB treatment mitigates histopathological changes of the liver in septic mice.** As shown in Fig. 1, no histological changes were evident in the sham group. In the CLP group, the liver exhibited severe destruction of the architecture, characterized by edema and necrosis, as well as neutrophil infiltration (Fig. 1A). The liver histopathological score of the CLP group was significantly elevated compared with that of the sham group. However, SalB treatment significantly attenuated the CLP-induced pathological changes (Fig. 1C). Following confirmation of the efficiency of SIRT1 siRNA transfection in the liver using western blotting (Fig. 1B), it was found that the protective effect of SalB was significantly reduced by SIRT1 siRNA in the CLP + SalB + SIRT1 siRNA group compared with the CLP + SalB + control siRNA group (Fig. 1C).

**SalB treatment lowers the serum levels of AST and ALT in septic mice.** Significantly increased serum levels of AST
and ALT were observed in the CLP group compared with the sham group, indicating that severe liver injury occurred in the CLP group. SalB treatment significantly decreased the serum levels of AST and ALT compared with those in the CLP group. However, co‑treatment with SIRT1 siRNA significantly attenuated the protective effect of SalB (Fig. 2).

SalB treatment decreases inflammatory cytokine production in septic mice. The serum levels of the inflammatory cytokines TNF-α and IL-6 were detected in order to evaluate the anti-inflammatory effects of SalB. The ELISA assay results (Fig. 3A and B) revealed that the levels of IL-6 and TNF-α were significantly increased in the CLP group compared with the sham group. However, SalB treatment significantly lowered these levels, and the attenuating effect of SalB was significantly reversed by co-treatment with SIRT1 siRNA. In addition, the RT-qPCR results shown in Fig. 3C and D revealed that the mice in the CLP group expressed significantly higher levels of IL-6 and TNF-α mRNA compared with those in the sham group, and the CLP-induced increases were significantly attenuated by SalB treatment. Co-treatment with SIRT1 siRNA significantly mitigated the protective effect of SalB.

SalB treatment suppresses MPO activity in the liver tissues of septic mice. MPO is a marker of neutrophil infiltration (21). Therefore, MPO activity was detected in order to evaluate the effect of SalB on the infiltration of neutrophils into the liver in septic mice. As shown in Fig. 4, MPO activity was
To elucidate whether SalB has the potential to alleviate hepatocyte apoptosis after sepsis, the expression levels of Bax and Bcl-2 were detected using RT-qPCR and western blotting. The present results showed that the mRNA and protein expression levels of Bax markedly increased compared with the sham group, while the mRNA and protein expression levels of Bcl-2 significantly decreased. The results indicated that the mRNA and protein expression levels of Bax were significantly reduced in the CLP + SalB group compared with the CLP group, while the expression levels of Bcl-2 mRNA and protein were significantly increased in the CLP + SalB group compared with the CLP group (Fig. 5). However, co-treatment with SIRT1 siRNA significantly attenuated the SalB-induced changes in the mRNA and protein levels of Bax and Bcl-2.

SalB treatment decreases caspase-3 activity in the liver tissues of septic mice. As shown in Fig. 6, caspase-3 activity was significantly increased in the CLP group compared with the sham group. However, the CLP-induced elevation of caspase-3 activity was significantly reduced by treatment with SalB. Furthermore, co-treatment of the SalB-treated CLP model mice with SIRT1 siRNA significantly increased MPO activity.

Figure 6. Effect of SalB on caspase-3 activity in septic mice. Data are expressed as the mean ± SEM (n=6/group). *P<0.05 vs. sham group, #P<0.05 vs. CLP group, &P<0.05 vs. CLP + SalB + control siRNA group. SalB, salvi-anolic acid B; CLP, cecal ligation and puncture; siRNA, small interfering RNA; SIRT1, sirtuin 1.

The results indicate that SalB was abolished by the co-administration of SIRT1 siRNA. Furthermore, MPO activity was measured in the present study, since MPO is an indicator of neutrophil infiltration. In addition, hepatocyte damage results in the release of AST and ALT (26). Consequently, the levels of AST and ALT in the serum were observed to be significantly elevated in the CLP group in the present study. However, pretreatment of the mice with SalB significantly decreased the serum levels of AST and ALT; this effect of SalB was abolished by the co-administration of SIRT1 siRNA. TNF-α and IL-6 are proinflammatory mediators and are regarded as diagnostic and prognostic biomarkers in septic patients (27). The results of the present study indicate that the mRNA and protein levels of TNF-α and IL-6 were increased significantly following the induction of sepsis. SalB pretreatment significantly decreased the CLP-induced levels of TNF-α and IL-6, an effect that was also abolished by SIRT1 siRNA. Furthermore, MPO activity was measured in the present study, since MPO is an indicator of neutrophil infiltration (28). The results suggest that SalB may decrease neutrophil infiltration following CLP-induced sepsis, and indicate that SalB protects against CLP-induced liver injury via the inhibition of the inflammatory response. Together, these results suggest that SalB treatment is able to ameliorate pathological changes of the liver and inflammatory reactions after sepsis induction, and that SIRT1 is potentially a critical molecule in the protective role of SalB.

Sepsis comprises two inflammatory phases, namely, the systemic inflammatory phase and the compensatory anti-inflammatory phase (25). The dysregulation of inflammation can lead to tissue and organ damage (17). In the present study, a CLP procedure was used to induce sepsis in mice. Sepsis led to severe pathological changes in the liver, which were characterized by edema and necrosis, as well as neutrophil infiltration. In addition, hepatocyte damage results in the release of AST and ALT (26). Consequently, the levels of AST and ALT in the serum were observed to be significantly elevated in the CLP group in the present study. However, pretreatment of the mice with SalB significantly decreased the serum levels of AST and ALT; this effect of SalB was abolished by the co-administration of SIRT1 siRNA. TNF-α and IL-6 are proinflammatory mediators and are regarded as diagnostic and prognostic biomarkers in septic patients (27). The results of the present study indicate that the mRNA and protein levels of TNF-α and IL-6 were increased significantly following the induction of sepsis. SalB pretreatment significantly decreased the CLP-induced levels of TNF-α and IL-6, an effect that was also abolished by SIRT1 siRNA. Furthermore, MPO activity was measured in the present study, since MPO is an indicator of neutrophil infiltration (28). The results suggest that SalB may decrease neutrophil infiltration following CLP-induced sepsis, and indicate that SalB protects against CLP-induced liver injury via the inhibition of the inflammatory response. Together, these results suggest that SalB treatment is able to ameliorate pathological changes of the liver and inflammatory reactions after sepsis induction, and that SIRT1 is potentially a critical molecule in the protective role of SalB.

Role of SIRT1/PGC-1α signaling in the protective effects of SalB. To evaluate the possible mechanisms underlying the effects of SalB on CLP, the expression levels of SIRT1 and PGC-1α were detected using western blotting. CLP decreased the expression levels of SIRT1 and PGC-1α. As shown in Fig. 7, SalB increased the expression levels of SIRT1 and PGC-1α in the CLP + SalB group compared with the CLP group. However, SIRT1 siRNA abolished this effect and clearly reduced the expression levels of SIRT1 and PGC-1α in the CLP + SalB + SIRT1 siRNA group. These results suggest that SalB confers a protective effect via the activation of SIRT1/PGC-1α signaling.

Discussion

In the current study, the aim was to investigate the effects of SalB on sepsis-induced liver injury. CLP is reported to be the gold standard model for use in sepsis research (22-24), and is now widely used in the study of sepsis in animals. The present study of CLP-induced sepsis revealed several notable findings. Treatment with SalB markedly mitigated sepsis-induced liver injury in the mice, as supported by attenuated pathological changes and lowered serum AST and ALT levels. SalB treatment also significantly inhibited inflammation, as indicated by its ability to lower the mRNA and protein levels of TNF-α and IL-6. Furthermore, SalB treatment significantly down-regulated Bax and upregulated Bcl-2, which suggests that it may have the ability to decrease sepsis-induced apoptosis. In addition, SalB may confer its protective effects via the activation of SIRT1/PGC-1α signaling.

Sepsis comprises two inflammatory phases, namely, the systemic inflammatory phase and the compensatory anti-inflammatory phase (25). The dysregulation of inflammation can lead to tissue and organ damage (17). In the present study, a CLP procedure was used to induce sepsis in mice. Sepsis led to severe pathological changes in the liver, which were characterized by edema and necrosis, as well as neutrophil infiltration. In addition, hepatocyte damage results in the release of AST and ALT (26). Consequently, the levels of AST and ALT in the serum were observed to be significantly elevated in the CLP group in the present study. However, pretreatment of the mice with SalB significantly decreased the serum levels of AST and ALT; this effect of SalB was abolished by the co-administration of SIRT1 siRNA. TNF-α and IL-6 are proinflammatory mediators and are regarded as diagnostic and prognostic biomarkers in septic patients (27). The results of the present study indicate that the mRNA and protein levels of TNF-α and IL-6 were increased significantly following the induction of sepsis. SalB pretreatment significantly decreased the CLP-induced levels of TNF-α and IL-6, an effect that was also abolished by SIRT1 siRNA. Furthermore, MPO activity was measured in the present study, since MPO is an indicator of neutrophil infiltration (28). The results suggest that SalB may decrease neutrophil infiltration following CLP-induced sepsis, and indicate that SalB protects against CLP-induced liver injury via the inhibition of the inflammatory response. Together, these results suggest that SalB treatment is able to ameliorate pathological changes of the liver and inflammatory reactions after sepsis induction, and that SIRT1 is potentially a critical molecule in the protective role of SalB.

Apoptosis is also associated with the pathogenesis of sepsis (29). Apoptosis is characterized by caspase activation and is independent of inflammatory effects (30). It has been indicated that the inhibition of apoptosis improves the survival rate and mitigates multiple-organ injury in septic mice (31). However, apoptosis can lead to the depletion of dendritic cells and lymphocytes after sepsis (32,33). The
marked loss of dendritic cells in sepsis markedly impairs B- and T-cell function, and leads to immune suppression after sepsis. Furthermore, the loss of B and T cells will markedly aggravate immune suppression (34). In the present study, the results indicate that SalB treatment significantly decreased Bax expression and caspase-3 activity and increased Bcl-2 expression in septic mice. However, SIRT1 siRNA abolished these effects of SalB. This suggests that SalB may exhibit an anti-apoptotic effect in sepsis via SIRT1 activation. However, apoptosis was not directly measured in the present study, which is a limitation of the present study.

SIRT1, a histone deacetylase, has been shown to confer protective effects in sepsis (35). PGC-1α, a SIRT1 downstream target, serves a key role in mitochondrial biogenesis (36). PGC-1α-induced mitochondrial biogenesis is pivotal to the maintenance of energy and metabolic requirements (37). In the present study, the treatment of septic mice with SalB induced the activation of SIRT1/PGC-1 signaling. It may be hypothesized that this mechanism underlies the attenuating effect of SalB on the injury induced by sepsis. When SIRT1 was blocked, the effect of SalB on SIRT1/PGC-1 signaling was abolished, suggesting that SalB confers protection against sepsis at least partly through the activation of SIRT1/PGC-1 signaling.

In conclusion, SalB exerts a protective effect in septic mice by diminishing pathological injury and reducing serum AST and ALT levels, inflammation and hepatic apoptosis. The underlying mechanism may be associated with the activation of SIRT1/PGC-1α signaling. These findings suggest that SalB has the potential to be a therapeutic agent for the treatment of liver injury induced by sepsis.

Acknowledgements
The authors would like to thank Dr Guangxin Liu (Department of General Surgery, The 175th Hospital of PLA, Zhangzhou, China) for his help in reviewing and editing the manuscript.

Funding
This study was supported by grant from the Ministry of Health of Xi'an City (grant no. J201701010).
Availability of data and materials
The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

Authors' contributions
HS performed experiments and revised the manuscript. ZM and AG performed experiments and analyzed the data. HW wrote the manuscript and designed the study. XY designed experiments. All authors read and approved the final version of the manuscript.

Ethics approval and consent to participate
Not applicable.

Patient consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

References
1. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, et al.: The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 315: 801-810, 2016.
2. Mayr FB, Yende S and Angus DC: Epidemiology of severe sepsis. Virulence 5: 4-11, 2014.
3. Gofton TE and Young GB: Sepsis-associated encephalopathy. Nat Rev Neurol 8: 557-566, 2012.
4. Jin L, Wang Q, Zhang H, Tai S, Liu H and Zhang D: A synthetic peptide AWRK6 alleviates lipopolysaccharide-induced liver injury. Int J Mol Sci 19: E2661, 2018.
5. Yang L, Zhang H and Chen P: Sulfur dioxide attenuates sepsis-induced cardiac dysfunction via inhibition of NLRP3 inflammasome activation in rats. Nitric Oxide 81: 11-20, 2018.
6. Hu Q, Knight PH, Ren Y, Ren H, Zheng J, Wu X, Ren J and Sawyer RG: The emerging role of stimulator of interferon genes signaling in sepsis: Inflammation, autophagy and cell death. Acta Physiol (Oxf) 225: e13194, 2018.
7. Kramer L, Jordan B, Drumli W, Bauer P and Metnitz PG: Austrian epidemiologic study on intensive care ASG: Incidence and prognosis of early hepatic dysfunction in critically ill patients-a prospective multicenter study. Crit Care Med 35: 1099-1104, 2007.
8. Yan J, Li S and Li S: The role of the liver in sepsis. Int Rev Immunol 33: 498-510, 2014.
9. Yao Y, Feng Y and Lin W: Systematic review and meta-analysis of randomized controlled trials comparing compound danshen dripping pills and isosorbide dinitrate in treating angiina pectoris. Int J Cardiol 182: 46-47, 2015.
10. Guo C, Yin Y, Duan J, Zha Y, Yan J, Wei G, Guan Y, Wu X, Wang Y, Xi M and Wen A: Neuroprotective effect and underlying mechanism of sodium danshensu [3-(3,4-dihydroxyphenyl) lactic acid from radix and rhizoma Salviae miltiorrhizae = danshen] against cerebral ischemia and reperfusion injury in rats. Phytomedicine 22: 283-289, 2015.
11. Xu S, Zhong A, Bu X, Ma H, Li W, Xu X and Zhang J: Salvinianolic acid B inhibits platelets-mediated inflammatory response in vascular endothelial cells. Thromb Res 135: 137-145, 2015.
12. Zhang JP, Zhang YY, Zhang Y, Gao YG, Ma JJ, Wang N, Wang JY, Xie Y, Zhang FH and Chu L: Salviae miltiorrhizae (Danshen) injection ameliorates iron overload-induced cardiac damage in mice. Planta Med 79: 744-752, 2013.
13. Yang CW, Liu H, Li XD, Sui SG and Liu YF: Salvinianolic acid B protects against acute lung injury by decreasing TRPM6 and TRPM7 expressions in a rat model of sepsis. J Cell Biochem 119: 2101-2111, 2018.
14. Escrivano-Lopez Î, Diaz-Moraes N, Iannantuoni F, Lopez-Domeenech S, de Marañón AM, Abad-Jimenez Z, Bañuls C, Rovira-Llopis S, Herançe JR, Rocha M and Victor VM: The mitochondrial antioxidant SS-31 increases SIRT1 levels and ameliorates inflammation, oxidative stress and leukocyte-endothelium interactions in type 2 diabetes. Sci Rep 8: 15862, 2018.
15. Ma R, Liang W, Sun Q, Qiu X, Lin Y, Ge X, Juaietaitiekae K, Xie M, Zhou J, Huang X, et al: Sirt1/Nrf2 pathway is involved in oocyte aging by regulating cyclin B1. Aging (Albany NY) 10: 2990-3004, 2018.
16. Zhang T, Chi Y, Kang Y, Lu H, Niu H, Liu W and Li Y: Resveratrol ameliorates podocyte damage in diabetic mice via SIRT1/PGC-1α mediated attenuation of mitochondrial oxidative stress. J Cell Physiol 234: 5033-5043, 2019.
17. Zhao L, An R, Yang Y, Yang X, Liu H, Yue L, Li X, Lin Y, Reiter RJ and Qu Y: Melatonin alleviates brain injury in mice subjected to cecal ligation and puncture via attenuating inflammation, apoptosis, and oxidative stress: The role of SIRT1 signaling. J Pineal Res 59: 230-239, 2015.
18. Gao XH, Xu XX, Fan R, Wang C, Sheng R, Xia YF and Dai Y: Qi-Shao-Shuang-Gan, a combination of astraagalus membranaceus saponins with paecoa lactifloria glycosides, ameliorates polymicrobial sepsis induced by cecal ligation and puncture in mice. Inflammation 34: 10-21, 2011.
19. Liu B, Juan Z, Li Q, Li K, Wang Z, Liu L, Tang L, Yi X, Wang H, Li C and Gao T: Baicalenol protects human melanocytes from H2O2-induced apoptosis via inhibiting mitochondria-dependent caspase activation and the p38 MAPK pathway. Free Radic Biol Med 53: 183-193, 2012.
20. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2−(Delta Delta CT) method. Methods 25: 402-408, 2001.
21. Wu X, Zhang B, Fan R, Zhao L, Wang Y, Zhang S, Kaye AD, Huang L and Pei J: U50,488H inhibits neutrophil accumulation and TNF-α induction induced by ischemia-reperfusion in rat heart. Cytokine 56: 503-507, 2011.
22. Dou K, Leeelahavichkul A, Yuen PS and Star RA: Animal models of sepsis and sepsis-induced kidney injury. J Clin Invest 119: 2868-2878, 2009.
23. Parker SJ and Watkins PE: Experimental models of gram-nega- tive sepsis. Br J Surg 88: 22-30, 2001.
24. Wichterman KA, Baue AE and Chaudry IH: Sepsis and septic shock-a review of laboratory models and a proposal. J Surg Res 29: 189-201, 1980.
25. Buras JA, Holmzann B and Sitkovsky M: Animal models of sepsis: Setting the stage. Nat Rev Drug Discov 4: 854 -865, 2005.
26. Yan M, Yu Y, Mao X, Feng J, Wang Y, Chen H, Xie K and Yu Y: Hydrogen gas inhalation attenuates sepsis-induced liver injury in a FUNDC1-dependent manner. Int Immunol 71: 61-67, 2019.
27. Bozza FA, Sall JI, Japiassu AM, Soares M, Assis EF, Gomes RN, Bozza MT, Castro-Faria-Neto HC and Bozza PT: Cytokine profiles as markers of disease severity in sepsis: A multiplex analysis. Crit Care 11: R49, 2007.
28. An R, Zhao L, Xu J, Xi C, Li H, Shen G, Zhang W, Zhang S and Sun L: Resveratrol alleviates sepsis-induced myocardial injury in mice by suppressing neutrophil accumulation, the induction of TNFα and myocardial apoptosis via activation of Sirt1. Mol Med Rep 14: 5297-5303, 2016.
29. Gao X, Yan X, Yin Y, Lin X, Zhang Q, Xie Y and Cao J: Therapeutic targeting of apoptosis inhibitor of macrophage (AIM)/CD5L in sepsis. J Immunol 168: 2493‑2500, 2002.
33. Hotchkiss RS, Tinsley KW, Swanson PE, Schmieg RE Jr, Hui JJ, Chang KC, Osborne DF, Freeman BD, Cobb JP, Buchman TG and Karl IE: Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. J Immunol 166: 6952-6963, 2001.

34. Bouras M, Asehnoune K and Roquilly A: Contribution of dendritic cell responses to sepsis-induced immunosuppression and to susceptibility to secondary pneumonia. Front Immunol 9: 2590, 2018.

35. Wei S, Gao Y, Dai X, Fu W, Cai S, Fang H, Zeng Z and Chen Z: SIRT1-mediated HMGB1 deacetylation suppresses sepsis-associated acute kidney injury. Am J Physiol Renal Physiol 1: F20-F21, 2018.

36. Ding M, Feng N, Tang D, Feng J, Li Z, Jia M, Liu Z, Gu X, Wang Y, Fu F and Pei J: Melatonin prevents Drp1-mediated mitochondrial fission in diabetic hearts through SIRT1-PGC1α pathway. J Pineal Res 65: e12491, 2018.

37. Yue L, Zhao L, Liu H, Li X, Wang B, Guo H, Gao L, Feng D and Qu Y: Adiponectin protects against glutamate-induced excitotoxicity via activating SIRT1-dependent PGC-1α expression in HT22 hippocampal neurons. Oxid Med Cell Longev 2016: 2957354, 2016.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.